( 34 - 36 ) A phase I study with multiple myeloma patients showed that the efficacy of perifosine plus lenalidomide-dexamethasone can be favorable, especially for patients with an increased basal rate of p-AKT. The gene discussed is AKT1; the disease is plasma cell myeloma.